|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: LRRC49 |
Gene summary for LRRC49 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | LRRC49 | Gene ID | 54839 |
| Gene name | leucine rich repeat containing 49 | |
| Gene Alias | PGs4 | |
| Cytomap | 15q23 | |
| Gene Type | protein-coding | GO ID | GO:0000226 | UniProtAcc | B7Z7G0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 54839 | LRRC49 | HTA12-15-2 | Human | Pancreas | PDAC | 4.41e-04 | 3.35e-01 | 0.2315 |
| 54839 | LRRC49 | HTA12-25-1 | Human | Pancreas | PDAC | 3.68e-04 | 3.89e-01 | 0.313 |
| 54839 | LRRC49 | HTA12-26-1 | Human | Pancreas | PDAC | 1.03e-14 | 6.03e-01 | 0.3728 |
| 54839 | LRRC49 | HTA12-29-1 | Human | Pancreas | PDAC | 4.01e-22 | 5.35e-01 | 0.3722 |
| 54839 | LRRC49 | HTA12-32-1 | Human | Pancreas | PDAC | 4.65e-02 | 6.42e-01 | 0.3624 |
| 54839 | LRRC49 | 048752_1579-all-cells | Human | Prostate | BPH | 2.02e-31 | 6.73e-01 | 0.1008 |
| 54839 | LRRC49 | 052095_1628-all-cells | Human | Prostate | BPH | 8.59e-10 | 3.33e-01 | 0.1032 |
| 54839 | LRRC49 | 052097_1595-all-cells | Human | Prostate | BPH | 9.40e-14 | 5.44e-01 | 0.0972 |
| 54839 | LRRC49 | 052099_1652-all-cells | Human | Prostate | BPH | 4.86e-09 | 4.47e-01 | 0.1038 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| LRRC49 | SNV | Missense_Mutation | novel | c.718A>C | p.Thr240Pro | p.T240P | Q8IUZ0 | protein_coding | tolerated(0.07) | possibly_damaging(0.462) | TCGA-A2-A0D1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD |
| LRRC49 | SNV | Missense_Mutation | novel | c.400A>C | p.Asn134His | p.N134H | Q8IUZ0 | protein_coding | tolerated(0.56) | benign(0.17) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| LRRC49 | SNV | Missense_Mutation | novel | c.1026G>T | p.Lys342Asn | p.K342N | Q8IUZ0 | protein_coding | deleterious(0) | possibly_damaging(0.614) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| LRRC49 | SNV | Missense_Mutation | novel | c.1636N>A | p.Glu546Lys | p.E546K | Q8IUZ0 | protein_coding | deleterious(0) | benign(0.3) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| LRRC49 | SNV | Missense_Mutation | novel | c.1590N>C | p.Gln530His | p.Q530H | Q8IUZ0 | protein_coding | deleterious(0.01) | probably_damaging(0.973) | TCGA-E2-A574-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| LRRC49 | insertion | Nonsense_Mutation | novel | c.19_20insAGTAACCAGATGCAAAATGAGTGCAAACAATGTTTAGAA | p.Arg7delinsGlnTerProAspAlaLysTerValGlnThrMetPheArgSer | p.R7delinsQ*PDAK*VQTMFRS | Q8IUZ0 | protein_coding | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| LRRC49 | SNV | Missense_Mutation | novel | c.1403N>C | p.Ile468Thr | p.I468T | Q8IUZ0 | protein_coding | tolerated(0.37) | benign(0.003) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| LRRC49 | SNV | Missense_Mutation | c.1617G>C | p.Gln539His | p.Q539H | Q8IUZ0 | protein_coding | tolerated(0.1) | possibly_damaging(0.605) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR | |
| LRRC49 | SNV | Missense_Mutation | c.642G>C | p.Arg214Ser | p.R214S | Q8IUZ0 | protein_coding | tolerated(0.21) | benign(0.048) | TCGA-IR-A3LH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| LRRC49 | SNV | Missense_Mutation | novel | c.1805N>A | p.Val602Glu | p.V602E | Q8IUZ0 | protein_coding | tolerated(0.36) | benign(0.003) | TCGA-UC-A7PG-06 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | PD |
| Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |